Business Context and Reporting Period
This Form 8-K is a current report filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on October 18, 2018, with the earliest event reported on that date. The filing addresses executive leadership changes within the company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on corporate governance and personnel changes.
Material Changes
- Departure of Chief Medical Officer: Dr. Joseph Stauffer, D.O., MBA, transitioned from the role of Chief Medical Officer to a consultant effective October 18, 2018.
- Appointment of New Chief Medical Officer: Dr. Joana Goncalves, MD, was appointed as the new Chief Medical Officer, effective October 22, 2018.
- Consulting Agreement: On October 22, 2018, Dr. Stauffer entered into a Separation and Consulting Agreement to provide services to the company for a period of up to nine months.
Guidance, Outlook, and Risks
The filing includes a press release (Exhibit 99.1) announcing the appointment of Dr. Goncalves. The document explicitly states that the information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings. No financial guidance, risk factors, or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the exact terms of the Separation and Consulting Agreement with Dr. Stauffer, including any severance or compensation details not fully elaborated in the 8-K.
- Review the full text of the press release (Exhibit 99.1) for additional context on Dr. Goncalves' background and strategic rationale for the appointment.
- Confirm the company's current ticker symbol and name, as the input metadata referenced "Tvardi Therapeutics" while the filing is for "Cara Therapeutics."